CoChat
Sign Up
Cited by 128Male Breast Health StudiesEstrogen and related hormone effectsHypothalamic control of reproductive hormones

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Safety and Efficacy of Anastrozole for the Treatment of Pubertal Gynecomastia: A Randomized, Double-Blind, Placebo-Controlled Trial

Plourde, Paul V., Reiter, Edward O., Jou, Hann-Chang, Desrochers, Paul E., Rubin, Stephen D., Bercu, Barry B., Diamond, Frank B., Backeljauw, Philippe F., Members of the AstraZeneca Gynecomastia Study·2004·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2004-0082
Open this paper in CoChat — free account

Abstract

Pubertal gynecomastia is thought to result from transient imbalances between estrogen and androgen concentrations. Anastrozole (ARIMIDEX), a potent and selective aromatase inhibitor, decreases estrogen and increases testosterone concentrations in pubertal boys. The safety and efficacy of anastrozole for the treatment of pubertal gynecomastia were evaluated. In a randomized, double-blind, placebo-controlled study of 80 boys, aged 11-18 yr, with pubertal gynecomastia that had not reduced over a 3-month interval, subjects received either anastrozole (1 mg) or placebo once daily for 6 months. A response was defined as a 50% or greater reduction in the calculated volume of both breasts combined using ultrasonography measurements. A comparison of response rates was performed using logistic regression analysis. Secondary end points included changes in serum hormone concentrations. The percentage of patients with a response was 38.5% for the anastrozole group and 31.4% for the placebo group (odds ratio, 1.513; 95% confidence interval, 0.496-4.844; P = 0.47). At 6 months, the median percent change in the testosterone/estradiol ratio was 166% for the anastrozole group and 39% for the placebo group. Anastrozole treatment was well tolerated. In patients with pubertal gynecomastia, no significant difference in the percentage of patients with a 50% or greater reduction in total breast volume, as calculated from ultrasonography measurements, was demonstrated between the anastrozole and placebo groups.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2004-0082

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 3

  1. Konig, 1987, Treatment of marked gynecomastia in puberty with tamoxifen., Klin Padiatr, 199, 389
  2. Swoboda, 1977, A new antigonadotropin in the treatment of precocious puberty and pubertal gynaecomastia, Padiatr Padol, 5, 109
  3. Swoboda, 1981, Steroid treatment of adolescent gynecomastia with danazol., Wien Med Wochenschr, 131, 127

Cited by

Sorted by citations

See all 128

Related

Metadata

Authors
Plourde, P. V., Reiter, E. O., Jou, H.-C., Desrochers, P. E., Rubin, S. D., Bercu, B. B., Diamond, F. B., Backeljauw, P. F., & Study, M. O. T. A. G.
Affiliations
  • AstraZeneca (United States) (US)
  • Baystate Medical Center (US)
  • University of South Florida (US)
  • Cincinnati Children's Hospital Medical Center (US)
Corresponding author
Plourde, Paul V.
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2004-09-01
Volume
89
Issue
9
Pages
4428-4433
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2004-0082
OpenAlex
W2117785194
Cited by
128
References
48
Citations by year
2026: 4 · 2025: 1 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 7 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 4
FWCI
8.11
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Male Breast Health Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
pubertal gynecomastia, anastrozole, aromatase inhibitors, testosterone/estradiol ratio, adolescent boys, drug safety and efficacy
MeSH terms
Anastrozole, Adolescent, Child, Double-Blind Method, Enzyme Inhibitors, Estradiol, Gynecomastia, Humans, Male, Nitriles, Testosterone, Triazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review